NIH R01 · 2024
Role of Foxa2 in ligand-dependent activation of nuclear receptors
Project Summary/Abstract Activation of nuclear receptors, a family of ligand-dependent transcription factors, is used extensively in pharmacology to develop drug targets for diverse medical conditions, including metabolic disease and cancer. While synthetic agonists and antagonists of nuclear receptors ameliorate symptoms of many diseases, clinical use of these compounds leads to frequent side effects that range in their severity. Type II receptors, such as FXR, LXR, and PPAR, which function in fatty acid, bile acid, cholesterol, and glucose metabolism, are permanently positioned in the nucleus regardless of the ligand status. The accepted paradigm regarding ligand activation of type II…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.